UA43854C2 - Фармацевтичний препарат для перорального прийому, спосіб одержання вказаного препарату (варіанти) та спосіб профілактики або лікування гіпертензії - Google Patents
Фармацевтичний препарат для перорального прийому, спосіб одержання вказаного препарату (варіанти) та спосіб профілактики або лікування гіпертензії Download PDFInfo
- Publication number
- UA43854C2 UA43854C2 UA96041718A UA96041718A UA43854C2 UA 43854 C2 UA43854 C2 UA 43854C2 UA 96041718 A UA96041718 A UA 96041718A UA 96041718 A UA96041718 A UA 96041718A UA 43854 C2 UA43854 C2 UA 43854C2
- Authority
- UA
- Ukraine
- Prior art keywords
- fact
- pharmaceutical preparation
- ramipril
- preparation according
- items
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 33
- 238000000034 method Methods 0.000 title claims description 21
- 230000002265 prevention Effects 0.000 title claims description 5
- 239000003814 drug Substances 0.000 title description 33
- 229940079593 drug Drugs 0.000 title description 32
- 238000002360 preparation method Methods 0.000 title description 5
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims abstract description 83
- 229960003401 ramipril Drugs 0.000 claims abstract description 83
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims abstract description 58
- 229960003580 felodipine Drugs 0.000 claims abstract description 58
- 206010020772 Hypertension Diseases 0.000 claims abstract description 15
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 14
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 14
- 229940127291 Calcium channel antagonist Drugs 0.000 claims abstract description 12
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims abstract description 9
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001597 nifedipine Drugs 0.000 claims abstract description 9
- 229960005425 nitrendipine Drugs 0.000 claims abstract description 9
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 claims abstract description 7
- 229960004340 lacidipine Drugs 0.000 claims abstract description 7
- 239000000480 calcium channel blocker Substances 0.000 claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims description 29
- 230000002035 prolonged effect Effects 0.000 claims description 29
- 239000002552 dosage form Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 230000007774 longterm Effects 0.000 claims description 9
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 8
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 8
- -1 dihydropyridine compound Chemical class 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 210000000748 cardiovascular system Anatomy 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 15
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000008187 granular material Substances 0.000 description 14
- 239000010410 layer Substances 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 230000035487 diastolic blood pressure Effects 0.000 description 12
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 12
- 230000035488 systolic blood pressure Effects 0.000 description 11
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 9
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 9
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 206010030124 Oedema peripheral Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 229940014003 ramipril and felodipine Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 101100313377 Caenorhabditis elegans stip-1 gene Proteins 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 4
- 101100313382 Dictyostelium discoideum stip-2 gene Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 229920002675 Polyoxyl Polymers 0.000 description 4
- 101100516335 Rattus norvegicus Necab1 gene Proteins 0.000 description 4
- 101150059016 TFIP11 gene Proteins 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 239000000473 propyl gallate Substances 0.000 description 4
- 229940075579 propyl gallate Drugs 0.000 description 4
- 235000010388 propyl gallate Nutrition 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010042957 Systolic hypertension Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940125400 channel inhibitor Drugs 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012758 Diastolic hypertension Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 description 1
- 229960002231 ramiprilat Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Фармацевтический состав, содержащий рамиприл в качестве ингибитора ангиотензинконвертирующего фермента и антагонист кальция, которым является одно из соединений дигидропиридина, в частности фелодипин, нитрендипин, нифедипин и лацидипин. Данный фармацевтический состав предназначен для лечения гипертензии.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9402924A SE9402924D0 (sv) | 1994-09-02 | 1994-09-02 | Novel pharmaceutical composition |
SE9402925A SE9402925D0 (sv) | 1994-09-02 | 1994-09-02 | Novel oral pharmaceutical composition |
SE9400972 | 1995-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA43854C2 true UA43854C2 (uk) | 2002-01-15 |
Family
ID=74166050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA96041718A UA43854C2 (uk) | 1994-09-02 | 1995-08-30 | Фармацевтичний препарат для перорального прийому, спосіб одержання вказаного препарату (варіанти) та спосіб профілактики або лікування гіпертензії |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA43854C2 (ru) |
-
1995
- 1995-08-30 UA UA96041718A patent/UA43854C2/uk unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2184563C2 (ru) | Твердая лекарственная форма, содержащая рамиприл в качестве ингибитора ангиотензинконвертирующего фермента, и соединение дигидропиридина | |
US5004613A (en) | Oral sustained release pharmaceutical formulation and process | |
US5073380A (en) | Oral sustained release pharmaceutical formulation and process | |
EP0312581B1 (en) | Pharmaceutical sustained release matrix and process | |
US5200193A (en) | Pharmaceutical sustained release matrix and process | |
KR100845660B1 (ko) | 서방성 파라세타몰 조성물 | |
EA009378B1 (ru) | Многослойная, диспергируемая во рту таблетка | |
KR20080033354A (ko) | 카르비도파 및 레보도파를 함유하는 고형의 연장 방출약학적 조성물 | |
IE66255B1 (en) | Slow-release pharmaceutical composition | |
CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
WO2010128525A2 (en) | A formulation of ivabradine for treating the cardiovascular disease | |
CA2628955A1 (en) | Compositions of stabilized ramipril in combination with another active agent | |
SK6452002A3 (en) | Oral dosage unit comprising mirtazapine | |
CN102247366B (zh) | 包括依那普利和非洛地平的药物组合物缓释制剂 | |
UA43854C2 (uk) | Фармацевтичний препарат для перорального прийому, спосіб одержання вказаного препарату (варіанти) та спосіб профілактики або лікування гіпертензії | |
US5077294A (en) | Products containing verapamil or gallopamil and prazosin | |
RU2267318C1 (ru) | Пролонгированный антиангинальный препарат изосорбида динитрата и способ его получения | |
RU2183116C1 (ru) | Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием | |
RU2252024C2 (ru) | Способ получения спазмолитического лекарственного средства | |
EP2848260B1 (en) | Novel formulations of thiocolchicoside | |
CN101239036A (zh) | 含有血管紧张素转化酶抑制剂雷米普利和二氢吡啶类化合物的新药物组合物 | |
RU2145222C1 (ru) | Фармацевтическая композиция, обладающая антигистаминным действием |